Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model

2002 ◽  
Vol 171 (2) ◽  
pp. 85-88 ◽  
Author(s):  
N. Finnegan ◽  
D. Toomey ◽  
C. Condron ◽  
H. P. Redmond ◽  
M. Da Costa ◽  
...  
Keyword(s):  
Interleukin 2 ◽  
Therapeutic Index ◽  
Murine Tumour ◽  
Tumour Model

Magnetic sentinel lymph node biopsy in a murine tumour model

2016 ◽  
Vol 12 (4) ◽  
pp. 1045-1052
Author(s):  
Muneer Ahmed ◽  
Taeseong Woo ◽  
Kaichi Ohashi ◽  
Toshiki Suzuki ◽  
Akiko Kaneko ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Lymph Node Biopsy ◽  
Murine Tumour ◽  
Tumour Model ◽  
Node Biopsy

scholarly journals Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.

1989 ◽  
Vol 170 (3) ◽  
pp. 1015-1020 ◽  
Author(s):  
D L Fraker ◽  
H N Langstein ◽  
J A Norton
Keyword(s):  
Neutralizing Antibodies ◽  
Tumor Necrosis ◽  
Pulmonary Metastases ◽  
Interleukin 2 ◽  
Passive Immunization ◽  
Therapeutic Index ◽  
Antitumor Effects ◽  
Tumor Bearing ◽  
And Control ◽  
Necrosis Factor

Passive immunization against TNF allowed non-tumor-bearing C3H/HEN mice and tumor-bearing C57BL/6 mice to tolerate significantly more doses of IL-2 before death (p less than 0.005 and p less than 0.001, respectively). The antitumor effect of IL-2 against both 3-d and 10-d pulmonary metastases was maintained in mice treated concurrently with neutralizing antibodies to TNF. In one experiment with 10-d pulmonary metastases, increased administration of IL-2 made possible by passive immunization against TNF significantly improved the antitumor response compared to equitoxic doses of IL-2 and control antibody. The results indicate that TNF is a mediator of IL-2 toxicity but contributes minimally to the antitumor effects of IL-2. Strategies to inhibit TNF may improve the therapeutic index of IL-2 as a neoplastic agent.

Quantitative and comparative study of haematoporphyrin-derived photosensitizers on a murine tumour model

1990 ◽  
Vol 5 (3) ◽  
pp. 309-316 ◽  
Author(s):  
Eberhard Unsöld ◽  
Christian Ell ◽  
Dieter Jocham ◽  
Ronald Sroka ◽  
Susanne Stocker
Keyword(s):  
Comparative Study ◽  
Murine Tumour ◽  
Tumour Model

Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.

1990 ◽  
Vol 8 (2) ◽  
pp. 319-324 ◽  
Author(s):  
G M Mavligit ◽  
A A Zukiwski ◽  
J U Gutterman ◽  
P Salem ◽  
C Charnsangavej ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Hepatic Artery ◽  
Tumor Regression ◽  
Interleukin 2 ◽  
Cell Activity ◽  
Therapeutic Index ◽  
Hepatic Artery Infusion ◽  
Equal Distribution ◽  
Lak Cell

In an attempt to improve the therapeutic index of recombinant interleukin-2 (rIL-2) by generating or activating lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) regionally and/or in situ, we randomly assigned 28 patients with liver metastases to receive rIL-2 by continuous infusion for 5 days via either the splenic artery or the hepatic artery. Clinically significant and lasting tumor regression was observed only in two of 28 patients (7%), one in each of the two treatment arms. The maximum-tolerated daily dosage of rIL-2 was 3 x 10(6) U/m2; beyond this dosage, toxicity was excessive. Peripheral LAK cell activity measured in vitro and clinical tumor regression did not correlate. This observation, coupled with the equal distribution of regressions between the two treatment arms, raises the possibility that tumor regression, rare though it may be in response to rIL-2 administration, is largely mediated by TIL activation and not by LAK cell generation.

Cdk8 deletion in the ApcMin murine tumour model represses EZH2 activity and accelerates tumourigenesis

2015 ◽  
Vol 237 (4) ◽  
pp. 508-519 ◽  
Author(s):  
Mark L McCleland ◽  
Tim M Soukup ◽  
Scot D Liu ◽  
Jonathan H Esensten ◽  
Felipe de Sousa e Melo ◽  
...  
Keyword(s):  
Murine Tumour ◽  
Tumour Model
Sign in / Sign up

Export Citation Format

Share Document